Podcast: Play in new window | Download (Duration: 11:08 — 12.2MB)
Subscribe: Apple Podcasts | Spotify | RSS
This episode of Biotalk is focused on Locust Walk’s 2023 First Quarter Market Conditions Report, in which we apply the latest […]
Podcast: Play in new window | Download (Duration: 41:12 — 45.4MB)
Subscribe: Apple Podcasts | Spotify | RSS
On this episode of Biotalk, Locust Walk welcomes Andrew Allen, M.D., Ph.D., Co-Founder, President, CEO, and board member of Gritstone
While these key pillars are not exhaustive and approaches may overlap between multiple, these areas have seen a great deal of innovation and attention from strategics and investors as a result.
Podcast: Play in new window | Download (Duration: 13:12 — 14.7MB)
Subscribe: Apple Podcasts | Spotify | RSS
Our first Biotalk podcast is focused on Locust Walk’s 2022 year-in-review market conditions, which was released the first day of JPMorgan
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2022 Year In Review Report applies the latest data to analyze current activities in the life sciences deal landscape.
The CAR-T and oncology cell therapy landscape has broadly seen significant continued development, with over 2,000 therapies in development and ~1,350 active trials globally
Induced pluripotent stem cell (iPSC) technology has the potential to transform the treatment landscape and bring curative options to patients. iPSC-derived cells have the potential to address a wide range of diseases and serve as a fertile ground for new investment opportunities
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 Year End Market Conditions Report applies the latest data to analyze current activities in the life sciences deal landscape.
Locust Walk has conducted an extensive study of mergers and acquisitions in biopharma completed in the past three years and uncovered an interesting trend leaders need to understand
Induced pluripotent stem cell (iPSC) research has encapsulated a global market of scientists, clinicians, and investors and has quickly become the foundation for new regenerative medicines.